1.Evidence-based clinical practice guideline for bone cement-augmented pedicle screw technique (version 2025)
Sihao HE ; Junchao XING ; Tongwei CHU ; Zhengqi CHANG ; Xigao CHENG ; Fei DAI ; Xiaobing JIANG ; Jie HAO ; Jiang HU ; Jinghui HUANG ; Tianyong HOU ; Fei LUO ; Bo LIAO ; Changqing LI ; Lei LIU ; Guodong LIU ; Peng LIU ; Sheng LU ; Weishi LI ; Yang LIU ; Zhen LIU ; Wei MEI ; Peifu TANG ; Bing WANG ; Bing WANG ; Ce WANG ; Hongli WANG ; Liang WANG ; Shengru WANG ; Xiaobin WANG ; Yang WANG ; Yingfeng WANG ; Zheng WANG ; Jianzhong XU ; Guoyong YIN ; Haiyang YU ; Qiang YANG ; Zhaoming YE ; Bin ZHANG ; Chengmin ZHANG ; Jun ZOU ; Qiang ZHOU ; Min ZHAO ; Rui ZHOU ; Xiaojun ZHANG ; Yongfei ZHAO ; Zhongrong ZHANG ; Zehua ZHANG ; Yingze ZHANG
Chinese Journal of Trauma 2025;41(11):1035-1047
For middle-aged and elderly patients with conditions such as spinal fractures and degenerative spinal diseases, spinal internal fixation is a core surgical procedure for reconstructing spinal stability, heavily relying on the biomechanical stability provided by pedicle screw systems. Whereas, these patients are often complicated by osteoporosis that can significantly compromise the stability of the bone-pedicle screw interface, leading to a marked increase in pedicle screw loosening and surgical failure rates. The bone cement-augmented pedicle screw technique, which involves injecting bone cement into the vertebral body or screw trajectory to optimize the mechanical properties of the bone-pedicle screw composite, has been proven to significantly enhance fixation strength and effectively prevent screw-related failures, thereby reducing the incidence of internal fixation failure in high-risk populations undergoing spinal fusion. However, the widespread clinical application of this technique has faced challenges such as inaccurate clinical decision-making (indication and contraindication selection), non-standardized operative practices, and insufficient awareness of complication prevention, resulting in considerable variability in clinical outcomes and even severe complications. To address this, Prof. Luo Fei from First Affiliated Hospital of Army Medical University initiated the project and the Chinese Association Orthopaedic Surgeons organized relevant experts to develop the Evidence-based clinical practice guideline for bone cement-augmented pedicle screw technique ( version 2025), based on current evidence. The guidelines put forward 8 recommendations regarding the clinical value, scope of application, and operational standards of the technique, aiming to provide evidence-based medical support and technical standardization for clinical decision-making.
2.Applications and prospects of 5G+helicopter medical rescue
Wei HAN ; Danni HUANG ; Junchao WANG ; Yuanting LI ; Changgen CHEN ; Xiang LI ; Zhongliang JI ; Qin LI ; Zhuang LI
Chinese Journal of Aerospace Medicine 2025;36(1):72-78
Objective:To review the applications of key technologies of 5G+helicopter medical rescue and predict future developments. Literature resource and selection Related literature in this field that was published at home and abroad. Literature quotation Forty articles published at home and abroad. Literature synthesis 5G+helicopter medical rescue is a new medical rescue model that integrates airborne 5G network technology, body area network disease awareness technology and 5G air-ground collaborative rapid diagnosis and treatment technology. It can shorten the time and space distance of medical rescue and improve the efficiency. The clinical applications of 5G+helicopter medical rescue, including the development of rescue schemes, daily and disaster scenarios 5G networking schemes, and air-ground collaborative emergency rescue information sharing platforms, have delivered remarkable results in the field of medical rescue. Despite the challenges facing 5G technology such as high cost and inconsistent technical standards, its development will promote innovation and progress in low-airspace helicopter medical rescue and offer more efficient, more accurate and safer rescue services. Conclusions:It is recommended that 5G network be given more weight, the auto-flight technology of helicopters developed, rescue command and dispatch platforms established, rescue personnel better-trained and supervision and safety guarantee be enhanced.
3.Predictive value of preoperative prognostic nutritional index on postoperative outcome after transarterial chemoembolization in hepatocellular carcinoma patients
Gang LI ; Genfa YI ; Wei ZHAO ; Junchao WANG ; Zhengxin DUAN
Journal of Practical Radiology 2025;41(1):114-118
Objective To explore the predictive value of preoperative prognostic nutritional index(PNI)for postoperative out-comes of patients with hepatocellular carcinoma(HCC)undergoing transarterial chemoembolization(TACE).Methods The clinical datas of 142 HCC patients treated with TACE as initial treatment were retrospectively collected.According to the cut-off value deter-mined by the receiver operating characteristic(ROC)curve,the preoperative systemic immune-inflammation index(SII),PNI,aspar-tate aminotransferase-neutrophil ratio(ANRI),aspartate aminotransferase-lymphocyte ratio(ALRI)and aspartate aminotransferase-platelet ratio(APRI)were divided into high group and low group,and their effects of TACE on postoperative outcome were ana-lyzed.Results Preoperative PNI was negatively correlated with liver function 1 week after TACE.Preoperative PNI and tumor size were independent risk factors for overall survival(OS).The PNI≥42.35 group was better than PNI<42.35 group(OS 28 months vs 10 months),the tumor size<5 cm was better than tumor size≥5 cm(OS 37 months vs 11 months),and the differences were statistically significant(P<0.05).PNI was an independent risk factor for progression-free survival(PFS).The PNI≥42.35 group was better than PNI<42.35 group(PFS 6 months vs 3 months),and the difference was statistically significant(P<0.05).Conclusion Preop-erative PNI has a certain prognostic value in HCC patients,and the OS and PFS of HCC patients with PNI<42.35 group after TACE are shorter.
4.Mechanism of Zuoguiwan in Inhibiting Osteoclast Activation Induced by Breast Cancer via Regulating p38 MAPK/ERK Signaling Pathway
Jianjiang FU ; Yinlong MEI ; Junchao MA ; Xiaocui ZHU ; Wei WANG ; Hong LYU
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(1):1-9
ObjectiveTo investigate the effects of Zuoguiwan on osteoclast activation induced by breast cancer and its mechanism. MethodsTo simulate breast cancer-induced osteoclastic bone metastasis, RAW264.7 cells were cultured in conditioned medium containing 50% supernatant of MDA-MB-231 breast cancer cells. The dosages of Zuoguiwan used in the experiment were sera containing 5% and 10% Zuoguiwan. Tartrate-resistant acid phosphatase (TRAP) staining was used to detect osteoclast activation. Enzyme-linked immunosorbent assay (ELISA) was used to measure Cathepsin K secretion from RAW264.7 cells. Real-time quantitative polymerase chain reaction (PCR) was used to detect the mRNA expression levels of osteocalcin (OCN) and bone sialoprotein (BSP). Immunoprecipitation was employed to detect the interaction between Runt-related transcription factor 2 (Runx2) and core binding factor β subunit (CBF-β). Western blot was used to assess the protein expression of Runx2, phosphorylated Runx2 (p-Runx2), extracellular signal-regulated kinases 1/2 (ERK1/2), p-ERK1/2, p38 mitogen-activated protein kinase (MAPK), p-p38 MAPK, and CBF-β. ResultsCompared with the blank group, the MDA-MB-231 cell supernatant group showed a significant increase in TRAP-positive cell counts and Cathepsin K secretion. Meanwhile, the expression levels of p-Runx2, Runx2-CBF-β interaction, BSP and OCN mRNA, p-p38 MAPK, and p-ERK1/2 proteins were significantly decreased (P<0.01). Compared with the MDA-MB-231 cell supernatant group, Zuoguiwan-containing sera significantly reduced TRAP-positive cell counts and Cathepsin K secretion (P<0.01), significantly increased p-Runx2, BSP and OCN mRNA expression, as well as p-p38 MAPK and p-ERK1/2 protein levels, and promoted the interaction between Runx2 and CBF-β (P<0.01). No significant change in Runx2 expression was observed. Compared to the blank group, the BVD-523 group showed significantly lower expression of p-p38 MAPK and p-ERK1/2 proteins (P<0.01). Compared with the BVD-523 group, both low and high concentration Zuoguiwan-containing sera groups showed significantly higher p-p38 MAPK expression (P<0.01), and the high concentration Zuoguiwan group also exhibited a significant increase in p-ERK1/2 expression (P<0.01), while no statistical difference was found in the low-dose group. ConclusionZuoguiwan inhibits osteoclast activation by inducing phosphorylation of the key transcriptional regulator Runx2 in intra-osteoclast bone formation, and this process is closely associated with the activation of the p38 MAPK/ERK signaling pathway.
5.Research progress in hepatic arterial perfusion chemotherapy for advanced hepatocellular carcinoma complicated by portal vein tumor thrombus
Zhengxin DUAN ; Junchao WANG ; Wei ZHAO
Journal of Interventional Radiology 2025;34(4):341-346
Pathologically,hepatocellular carcinoma(HCC)is prone to invade the portal vein and form portal vein tumor thrombus(PVTT).Although great advances in the treatment of HCC have been achieved in recent years,HCC patients with PVTT still have limited therapeutic options and poor prognosis.Hepatic arterial infusion chemotherapy(HAIC)is a therapeutic approach that combines local therapy with systemic antitumor effects,and a lot of studies have shown that HAIC carries certain survival benefit to patients with advanced HCC complicated by PVTT,and it is considered to be an effective local therapy for advanced HCC,especially for patients with type Vp3-4 HCC.Systemic therapy is the main treatment for advanced HCC,but the diversity of HAIC combined with targeted and immunotherapy may become a more effective treatment option for HCC with severe PVTT,and it is possible to achieve a tumor-free state through translational therapy,allowing patients with advanced HCC to survive for a longer time.This article aims to summarize the research progress in HAIC for advanced HCC complicated by PVTT.
6.Application of TEG-PM and drug-related gene detection in guiding the selection of antiplatelet regimens in patients with intracranial aneurysms after receiving stenting
Xuerou MENG ; Wenqiu PAN ; Cheng WAN ; Genfa YI ; Junchao WANG ; Jihong HU ; Wei ZHAO
Journal of Interventional Radiology 2025;34(5):461-467
Objective To discuss the application of partial antiplatelet drug genotype detection and thromboelastography-platelet mapping(TEG-PM)in guiding the selection of antiplatelet regimens in patients with intracranial aneurysms(IAs)after receiving stenting.Methods A total of 106 patients with IAs in the First Affiliated Hospital of Kunming Medical University,who underwent implantation of stent and received the testings of platelet-endothelial aggregation receptor 1(PEAR 1)and clopidogrel-related gene-cytochrome P450 enzyme 2C19(CYP2C19),and some of whom received TEG-PM testing from January 2019 to August 2022,were collected for this study.The patients were divided into group A(gene detection group,according to the drug-related gene detection results to adjust the medication)and group B(combination group,according to the two testing results to guide the medication).The patient's gender,age,testing data were collected,and the occlusion of IAs,stent intimal hyperplasia,drug-related hemorrhagic and ischemic complications during follow-up period were recorded.Results A total of 123 IAs lesions in 106 patients were treated.The patient's mean age was(53.67±6.66)years,67 patients were female.Group A had 41 patients and group B had 65 patients.No statistically significant differences in the baseline data,IAs features,stent types used,and medication regimen existed between the two groups(all P>0.05).In Group A,the ischemic complications and hemorrhagic complications occurred in two patients each.In Group B,no ischemic complications occurred and 4 patients developed hemorrhagic complications.The difference in the incidence of related complications between the two groups was not statistically significant(P=0.287 and P=0.782 respectively).There were no statistically significant differences in the postoperative one-month and 3-month intimal hyperplasia grade and the aneurysm occlusion rate between the two groups(all P>0.05).The postoperative 6-month overall intimal hyperplasia grade in Group A was slightly higher than that in Group B,and the difference was statistically significant(P=0.034).Conclusion In order to improve the precision and individualized treatment of antiplatelet therapy,it is suggested that clinicians should adopt TEG-PM-guided conventional double-antibody therapy first when making selection of testing items.For patients with insufficient inhibition rate indicated by TEG-PM,testing of the genes associated with antiplatelet drugs should be used.Based on the genetic test results it is necessary to determine the reasons for the insufficient inhibition rate as well as to adjust the medication promptly according to the specific situation of the patient,so as to ensure the effectiveness of antiplatelet therapy and achieve the purpose of individualized precision therapy.
7.Antiviral effect of Lopinavir against porcine hemagglutinated encephalomyelitis virus
Yanfang YU ; Yihan TIAN ; Jianwei WEI ; Zi LI ; Junchao SHI ; Feng GAO ; Wenqi HE
Chinese Journal of Veterinary Science 2025;45(8):1720-1726
This study explores the antiviral effects of Lopinavir on porcine hemagglutinating en-cephalomyelitis virus(PHEV)in vitro and in vivo.Using PHEV-infected N2a cells as an in vitro experimental model,the impact of varying concentrations of Lopinavir on PHEV replication was analyzed through Western blot and qRT-PCR techniques.The results demonstrated that Lopinavir was beneficial to PHEV replication at low-concentration,but as the concentration increased,Lopi-navir began to exert an inhibitory effect,with the most pronounced effect observed at a concentra-tion of 8 μmol/L.PHEV-infected 3-week-old male BALB/c mice were utilized in vivo experi-ments,with Lopinavir(10 mg/kg)administered intragastrically three days post-infection.Follow-ing the onset of illness in the control group,all mice were euthanized,and brain tissues were col-lected for histopathological examination.The findings indicated that Lopinavir significantly reduced the distribution of PHEV and ameliorated the pathological damage in brain tissue,and prolonged the survival time of the mice.In conclusion,Lopinavir exhibits an antiviral effect against PHEV both in vitro and in vivo,offering a theoretical basis for the prevention and treatment of PHEV in-fections in clinical practice.
8.Antiviral effect of Lopinavir against porcine hemagglutinated encephalomyelitis virus
Yanfang YU ; Yihan TIAN ; Jianwei WEI ; Zi LI ; Junchao SHI ; Feng GAO ; Wenqi HE
Chinese Journal of Veterinary Science 2025;45(8):1720-1726
This study explores the antiviral effects of Lopinavir on porcine hemagglutinating en-cephalomyelitis virus(PHEV)in vitro and in vivo.Using PHEV-infected N2a cells as an in vitro experimental model,the impact of varying concentrations of Lopinavir on PHEV replication was analyzed through Western blot and qRT-PCR techniques.The results demonstrated that Lopinavir was beneficial to PHEV replication at low-concentration,but as the concentration increased,Lopi-navir began to exert an inhibitory effect,with the most pronounced effect observed at a concentra-tion of 8 μmol/L.PHEV-infected 3-week-old male BALB/c mice were utilized in vivo experi-ments,with Lopinavir(10 mg/kg)administered intragastrically three days post-infection.Follow-ing the onset of illness in the control group,all mice were euthanized,and brain tissues were col-lected for histopathological examination.The findings indicated that Lopinavir significantly reduced the distribution of PHEV and ameliorated the pathological damage in brain tissue,and prolonged the survival time of the mice.In conclusion,Lopinavir exhibits an antiviral effect against PHEV both in vitro and in vivo,offering a theoretical basis for the prevention and treatment of PHEV in-fections in clinical practice.
9.Predictive value of preoperative prognostic nutritional index on postoperative outcome after transarterial chemoembolization in hepatocellular carcinoma patients
Gang LI ; Genfa YI ; Wei ZHAO ; Junchao WANG ; Zhengxin DUAN
Journal of Practical Radiology 2025;41(1):114-118
Objective To explore the predictive value of preoperative prognostic nutritional index(PNI)for postoperative out-comes of patients with hepatocellular carcinoma(HCC)undergoing transarterial chemoembolization(TACE).Methods The clinical datas of 142 HCC patients treated with TACE as initial treatment were retrospectively collected.According to the cut-off value deter-mined by the receiver operating characteristic(ROC)curve,the preoperative systemic immune-inflammation index(SII),PNI,aspar-tate aminotransferase-neutrophil ratio(ANRI),aspartate aminotransferase-lymphocyte ratio(ALRI)and aspartate aminotransferase-platelet ratio(APRI)were divided into high group and low group,and their effects of TACE on postoperative outcome were ana-lyzed.Results Preoperative PNI was negatively correlated with liver function 1 week after TACE.Preoperative PNI and tumor size were independent risk factors for overall survival(OS).The PNI≥42.35 group was better than PNI<42.35 group(OS 28 months vs 10 months),the tumor size<5 cm was better than tumor size≥5 cm(OS 37 months vs 11 months),and the differences were statistically significant(P<0.05).PNI was an independent risk factor for progression-free survival(PFS).The PNI≥42.35 group was better than PNI<42.35 group(PFS 6 months vs 3 months),and the difference was statistically significant(P<0.05).Conclusion Preop-erative PNI has a certain prognostic value in HCC patients,and the OS and PFS of HCC patients with PNI<42.35 group after TACE are shorter.
10.Evidence-based clinical practice guideline for bone cement-augmented pedicle screw technique (version 2025)
Sihao HE ; Junchao XING ; Tongwei CHU ; Zhengqi CHANG ; Xigao CHENG ; Fei DAI ; Xiaobing JIANG ; Jie HAO ; Jiang HU ; Jinghui HUANG ; Tianyong HOU ; Fei LUO ; Bo LIAO ; Changqing LI ; Lei LIU ; Guodong LIU ; Peng LIU ; Sheng LU ; Weishi LI ; Yang LIU ; Zhen LIU ; Wei MEI ; Peifu TANG ; Bing WANG ; Bing WANG ; Ce WANG ; Hongli WANG ; Liang WANG ; Shengru WANG ; Xiaobin WANG ; Yang WANG ; Yingfeng WANG ; Zheng WANG ; Jianzhong XU ; Guoyong YIN ; Haiyang YU ; Qiang YANG ; Zhaoming YE ; Bin ZHANG ; Chengmin ZHANG ; Jun ZOU ; Qiang ZHOU ; Min ZHAO ; Rui ZHOU ; Xiaojun ZHANG ; Yongfei ZHAO ; Zhongrong ZHANG ; Zehua ZHANG ; Yingze ZHANG
Chinese Journal of Trauma 2025;41(11):1035-1047
For middle-aged and elderly patients with conditions such as spinal fractures and degenerative spinal diseases, spinal internal fixation is a core surgical procedure for reconstructing spinal stability, heavily relying on the biomechanical stability provided by pedicle screw systems. Whereas, these patients are often complicated by osteoporosis that can significantly compromise the stability of the bone-pedicle screw interface, leading to a marked increase in pedicle screw loosening and surgical failure rates. The bone cement-augmented pedicle screw technique, which involves injecting bone cement into the vertebral body or screw trajectory to optimize the mechanical properties of the bone-pedicle screw composite, has been proven to significantly enhance fixation strength and effectively prevent screw-related failures, thereby reducing the incidence of internal fixation failure in high-risk populations undergoing spinal fusion. However, the widespread clinical application of this technique has faced challenges such as inaccurate clinical decision-making (indication and contraindication selection), non-standardized operative practices, and insufficient awareness of complication prevention, resulting in considerable variability in clinical outcomes and even severe complications. To address this, Prof. Luo Fei from First Affiliated Hospital of Army Medical University initiated the project and the Chinese Association Orthopaedic Surgeons organized relevant experts to develop the Evidence-based clinical practice guideline for bone cement-augmented pedicle screw technique ( version 2025), based on current evidence. The guidelines put forward 8 recommendations regarding the clinical value, scope of application, and operational standards of the technique, aiming to provide evidence-based medical support and technical standardization for clinical decision-making.

Result Analysis
Print
Save
E-mail